Insider Chart Past 6 Months
Technical Chart
Filings by transaction date
-
Mar 27, 2024 (filed on Mar 28, 2024)Insider Name:Rogers BruceOwnership Type:Direct OwnershipSecurities:Stock Option (right to buy Common Stock)Nature of Transaction:M - Exercise or conversion exempt under rule 16b-3# or value acquired/disposed of:-7,400Price:--
-
Mar 27, 2024 (filed on Mar 28, 2024)Insider Name:Rogers BruceOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:M - Exercise or conversion exempt under rule 16b-3# or value acquired/disposed of:7,400Price:$4.32
-
Mar 18, 2024 (filed on Mar 19, 2024)Insider Name:Cooper Simon PeterOwnership Type:Direct OwnershipSecurities:Restricted Stock UnitNature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:7,000Price:--
-
Mar 18, 2024 (filed on Mar 19, 2024)Insider Name:Cooper Simon PeterOwnership Type:Direct OwnershipSecurities:Restricted Stock UnitNature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:14,000Price:--
-
Mar 18, 2024 (filed on Mar 19, 2024)Insider Name:Cooper Simon PeterOwnership Type:Direct OwnershipSecurities:Employee Stock Options (right to buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:170,000Price:--
-
Jan 16, 2024 (filed on Jan 17, 2024)Insider Name:Tipirneni Praveen P.Ownership Type:Direct OwnershipSecurities:Common StockNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-13,923Price:$27.49
-
Jan 16, 2024 (filed on Jan 17, 2024)Insider Name:Schegerin MarcOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-6,041Price:$27.49
-
Jan 16, 2024 (filed on Jan 17, 2024)Insider Name:Rogers BruceOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-6,314Price:$27.49
-
Jan 16, 2024 (filed on Jan 17, 2024)Insider Name:Farrell Robert E JrOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-5,089Price:$27.49
-
Jan 16, 2024 (filed on Jan 17, 2024)Insider Name:DeVaul WilliamOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-4,509Price:$27.49
Filings by filing date
-
Mar 27, 2024 (filed on Mar 28, 2024)Insider Name:Rogers BruceOwnership Type:Direct OwnershipSecurities:Stock Option (right to buy Common Stock)Nature of Transaction:M - Exercise or conversion exempt under rule 16b-3# or value acquired/disposed of:-7,400Price:--
-
Mar 27, 2024 (filed on Mar 28, 2024)Insider Name:Rogers BruceOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:M - Exercise or conversion exempt under rule 16b-3# or value acquired/disposed of:7,400Price:$4.32
-
Mar 18, 2024 (filed on Mar 19, 2024)Insider Name:Cooper Simon PeterOwnership Type:Direct OwnershipSecurities:Restricted Stock UnitNature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:7,000Price:--
-
Mar 18, 2024 (filed on Mar 19, 2024)Insider Name:Cooper Simon PeterOwnership Type:Direct OwnershipSecurities:Restricted Stock UnitNature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:14,000Price:--
-
Mar 18, 2024 (filed on Mar 19, 2024)Insider Name:Cooper Simon PeterOwnership Type:Direct OwnershipSecurities:Employee Stock Options (right to buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:170,000Price:--
-
Jan 14, 2024 (filed on Jan 17, 2024)Insider Name:Tipirneni Praveen P.Ownership Type:Direct OwnershipSecurities:Restricted Stock UnitNature of Transaction:M - Exercise or conversion exempt under rule 16b-3# or value acquired/disposed of:-12,500Price:--
-
Jan 13, 2024 (filed on Jan 17, 2024)Insider Name:Tipirneni Praveen P.Ownership Type:Direct OwnershipSecurities:Restricted Stock UnitNature of Transaction:M - Exercise or conversion exempt under rule 16b-3# or value acquired/disposed of:-29,500Price:--
-
Jan 12, 2024 (filed on Jan 17, 2024)Insider Name:Tipirneni Praveen P.Ownership Type:Direct OwnershipSecurities:Restricted Stock UnitNature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:136,800Price:--
-
Jan 12, 2024 (filed on Jan 17, 2024)Insider Name:Tipirneni Praveen P.Ownership Type:Direct OwnershipSecurities:Stock Option (right to buy Common Stock)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:206,400Price:--
-
Jan 16, 2024 (filed on Jan 17, 2024)Insider Name:Tipirneni Praveen P.Ownership Type:Direct OwnershipSecurities:Common StockNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-13,923Price:$27.49
News
Biz Brief
Sector: Healthcare | Industry: Biotechnology & Medical Research |
See Regulatory Filings on SEC |
Company Contact | |
Address: | 35 GATEHOUSE DRIVE A2 WALTHAM MA 02451 |
Tel: | N/A |
Website: | https://morphictx.com |
IR: | See website |
Key People | ||
Bruce N. Rogers President | Praveen P. Tipirneni Chief Executive Officer, Director | Marc Schegerin Chief Financial Officer, Chief Operating Officer |
Robert E. Farrell Senior Vice President - Finance, Chief Accounting Officer | William David DeVaul General Counsel, Secretary |
Business Overview |
Morphic Holding, Inc. is a biopharmaceutical company. The Company is engaged in discovering and developing a pipeline of potentially oral small molecule integrin therapeutics for the treatment of serious chronic diseases, including autoimmune, cardiovascular and metabolic diseases, fibrosis and cancer. The Company's Morphic integrin technology platform (MInT Platform) helps to develop product candidates designed to achieve the potency, high selectivity and pharmaceutical properties required for oral administration. The Company is advancing its pipeline, including its lead product candidate, MORF-057, an orally administered a4b7-specific integrin inhibitor affecting inflammation, into clinical development for the treatment of inflammatory bowel disease (IBD). It has also developed avb6-specific integrin inhibitors for the treatment of fibrotic diseases including idiopathic pulmonary fibrosis (IPF) and additional indications. |
Financial Overview |
For the three months ended 31 March 2024, Morphic Holding Inc revenues decreased from $521K to $0K. Net loss increased 25% to $45.3M. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Higher net loss reflects Research and development - B increase of 38% to $35.6M (expense), Stock-based Compensation in R&D increase of 47% to $6.8M (expense). |
Employees: | 124 as of Mar 31, 2024 |
Reporting Currency: | U.S. Dollars |
Enterprise value: | $839.03M as of Mar 31, 2024 |
Annual revenue (TTM): | $0.00M as of Mar 31, 2024 |
EBITDA (TTM): | -$191.97M as of Mar 31, 2024 |
Net annual income (TTM): | -$161.25M as of Mar 31, 2024 |
Free cash flow (TTM): | -$128.61M as of Mar 31, 2024 |
Net Debt Last Fiscal Year: | N/A |
Shares outstanding: | 50,093,588 as of Mar 31, 2024 |
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization |